Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Protalix Biotherapeutics Inc V.PLX.H


Primary Symbol: PLX

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.


NYSEAM:PLX - Post by User

Post by stockfyon Apr 04, 2019 6:44am
184 Views
Post# 29580414

My previous bullish PLX call & my new bullish call on TVL

My previous bullish PLX call & my new bullish call on TVLIt was me who has posted many factual comments explaining why PLX was grossly undervalued at C$0.17 a few weeks ago.  PLX is at C$0.23 now and rising. 

See also Traverse Energy (TVL) before it's too late.

TVL is irrationally undervalued at C$0.06 per share because TVL owns 100,000 net acres in Duvernay. 

TVL current enterprise value at C$0.06 per share is just C$11 million including its small debt but its Duvernay acreage alone at just C$500 per acre is valued C$50 million.

TVL's insiders have a lot of skin in the game and have been buying during the last months, so they own about 30%, so they are fully aligned with shareholders.

TVL has said that it's working on options to develop and monetize its Duvernay acreage, so farm-outs or an outright sale are very likely.

InPlay (IPO) that also owns Duvernay acreage close to TVL announced in its latest press release that its Duvernay acreage is valued at C$1,619 per acre by the indepent firm Seaton-Jordan Partners:
 
"Strategic Crown land holdings in the East Duvernay light oil shale play increased by 12 sections for consideration of $1.4 million in the year.  The Company now has a significant land position in one of the most exciting new Canadian light oil plays with 30,640 net acres (48.25 net sections). An independent report was prepared for InPlay on this land by qualified land evaluators, Seaton-Jordan & Associates, which  resulted in a value of $49.6 million at year-end."
 
and:
 
"Based on Sproule’s forecast prices and costs as of December 31, 2018.
Duvernay land holdings evaluated by independent third party firm Seaton-Jordan Partners effective December 31, 2018 attributed a value of $49.6 mm ($1,619/acre) for 30,720 net acres. "
 

<< Previous
Bullboard Posts
Next >>